USE OF OPIOID RECEPTOR ANTAGONIST WITH K-ACTIVITY AND VORTIOXETINE FOR TREATMENT OF DEPRESSIVE DISORDER WITH MELANCHOLIC FEATURES

• 1. 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途 [P] . 中国专利： CN105828821B . 2019.04.09
• 2. 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途 [P] . 中国专利： CN105828821A . 2016-08-03
• 3. APPLICATION OF OPIOID RECEPTOR ANTAGONISTS WITH K-ACTIVITY AND VORTIOXETINE FOR TREATMENT OF DEPRESSIVE DISORDER WITH MELANCHOLIC SIGNS [P] . 俄罗斯专利： RU2016123972A . 2018-01-25

  机译： 具有K活性和伏立西汀的阿片受体拮抗剂在治疗忧郁症伴抑郁症中的应用

• 4. USE OF AN OPIOID RECEPTOR ANTAGONIST WITH KAPPA-ACTIVITY AND VORTIOXETINE FOR TREATMENT OF DEPRESSIVE DISORDER WITH MELANCHOLIC FEATURES. [P] . MX368870B . 2019-10-21

  机译： 具有卡帕活性的阿片受体拮抗剂和伏立西汀在治疗忧郁性抑郁症中的应用。

• 5. Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features [P] . AU2014368548B2 . 2019-09-19

  机译： 具有κ活性和伏替西汀的阿片受体拮抗剂在治疗具有忧郁特征的抑郁症中的用途

• 1. Kappa opioid receptor antagonist and N-methyl-D- aspartate receptor antagonist affect dynorphin- induced spinal cord electrophysiologic impairment [J] . Yu Chen, Liangbi Xiang, Jun Liu, 中国神经再生研究（英文版） . 2012,第007期
• 2. A combined marker of early non-improvement and the occurrence of melancholic features improve the treatment prediction in patients with Major Depressive Disorders [J] . Wagner Stefanie, Tadic Andre, Roll Sibylle C., Journal of affective disorders . 2017,第期
• 3. Melancholic features in inpatients with major depressive disorder associate with differential clinical characteristics and treatment outcomes [J] . Lin Ching-Hua, Huang Chun-Jen, Liu Shi-Kai Psychiatry research . 2016,第Null期
• 4. Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features [J] . Craig H Mallinckrodt, John G Watkin, Chaofeng Liu, BMC Psychiatry . 2005,第1期
• 5. Identification of opioid receptor ligand interactions using structurally related delta-opioid receptor agonists and antagonists and molecular modeling. [C] . Sharon D.Bryant, Yunden Jinsmaa, Lawrence H.Lazarus International Peptide Symposium;European Peptide Symposium . 2005
• 6. Using Early Changes in Cognition to Predict Response to 8-week Vortioxetine Treatment in Patients with Major Depressive Disorder [D] . Park, Caroline. 2019
• 7. Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features [O] . Craig H Mallinckrodt, John G Watkin, Chaofeng Liu, 1946
• 8. Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features [O] . Wohlreich Madelaine M, Liu Chaofeng, Watkin John G, 2005

• 1. Evaluation Efficacy and Safety of Vortioxetine 20 mg/d versus Placebo for Treatment Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [J] . Masoud Behzadifar ,Hamidreza Dehghan ,Korush Saki . 药理与制药（英文） . 2015,第4期
• 2. Efficacy and Safety of Vortioxetine and Duloxetine 60 mg Compared Placebo for the Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis [J] . Masoud Behzadifar ,Abouzar Keshavarzi ,Abed Tofighian . 行为与脑科学期刊（英文） . 2015,第10期
• 3. Nuclear receptors modulate inflammasomes in the pathophysiology and treatment of major depressive disorder [J] . Han Wang ,Wei-Jing Kan ,Yuan Feng . 世界精神病学杂志 . 2021,第12期
• 4. Levomilnacipran and vortioxetine： Review of new pharmacotherapies for major depressive disorder [J] . Mei T Liu ,Megan E Maroney ,Evelyn R Hermes-DeSantis . 世界药理学杂志 . 2015,第001期
• 5. 度洛西汀与艾司西酞普兰治疗抑郁症的临床可行性 [C] . 王灿灿 ,曾昭平 . 《中医杂志》特邀心血管专家学术座谈会暨中医治疗冠心病心绞痛疾病临床经验会议 . 2017
• 6. 艾司西酞普兰与度洛西汀治疗抑郁症有效性和安全性的Meta分析 [A] . 路淑淑 . 2020